Table 1.

Multivariate analysis of intratumoral CD38⁺ plasma cell and CD20⁺ B cell density with survival outcomes in triple negative breast cancer (TNBC) patients.

	Hazard ratio	95% confidence interval	pValue
Disease-free survival (DFS)
Intratumoral CD38+ plasma cell TNBCs High vs. low	0.44	(0.26, 0.77)	0.004*
Intratumoral CD38+ plasma cell TNBCs (every 1 percent)	0.95	(0.93, 0.98)	0.002*
Intratumoral CD20+ B cell TNBCs High vs. low	0.50	(0.25, 0.99)	0.046*
Intratumoral CD20+ B cell TNBCs (every 1 percent)	0.98	(0.95, 1.01)	0.228
Overall survival (OS)
Intratumoral CD38+ plasma cell TNBCs High vs. low	0.66	(0.36, 1.2)	0.171
Intratumoral CD38+ plasma cell TNBCs (every 1 percent)	0.98	(0.96, 1.01)	0.187
Intratumoral CD20+ B cell TNBCs High vs. low	0.42	(0.19, 0.97)	0.042*
Intratumoral CD20+ B cell TNBCs (every 1 percent)	1.00	(0.96, 1.03)	0.792

Analysis was adjusted for tumor size, grade, age, and lymph node status.

*Statistically significant.